Albert Sleiman Mellick

Dr. Albert Sleiman Mellick


Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2008 in Science
Verified
Journal Article
Closed access
PDF file
DGDingcheng Gao
Dingcheng Gao
DNDaniel J. Nolan
Daniel J. Nolan
AMAlbert Sleiman Mellick
Albert Sleiman Mellick
KBKathryn Bambino
Kathryn Bambino
KMKevin McDonnell
Kevin McDonnell
VMVivek Mittal
Vivek Mittal
Angiogenesis-mediated progression of micrometastasis to lethal macrometastasis is the major cause of death in cancer patients. Here, using mouse models of pulmonary metastasis, we identify bone marrow (BM)–derived endothelial progenitor cells (EPCs) as critical regulators of this angiogenic switch. We show that tumors induce expression of the transcription factor Id1 in the EPCs and that suppression of Id1 after metastatic colonization blocked EPC mobilization, caused angiogenesis inhibition, impaired pulmonary macrometastases, and increased survival of tumor-bearing animals. These findings establish the role of EPCs in metastatic progression in preclinical models and suggest that selective targeting of EPCs may merit investigation as a therapy for cancer patients with lung metastases.

15 June 2007 in Genes & Development
Verified
Journal Article
Closed access
PDF file
DNDaniel J. Nolan
Daniel J. Nolan
ACAlessia Ciarrocchi
Alessia Ciarrocchi
AMAlbert Sleiman Mellick
Albert Sleiman Mellick
JJJaspreet S. Jaggi
Jaspreet S. Jaggi
KBKathryn Bambino
Kathryn Bambino
VMVivek Mittal
Vivek Mittal
Tumors build vessels by cooption of pre-existing vasculature and de novo recruitment of bone marrow (BM)-derived endothelial progenitor cells (EPCs). However, the contribution and the functional role of EPCs in tumor neoangiogenesis are controversial. Therefore, by using genetically marked BM progenitor cells, we demonstrate the precise spatial and temporal contribution of EPCs to the neovascularization of three transplanted and one spontaneous breast tumor in vivo using high-resolution microscopy and flow cytometry. We show that early tumors recruit BM-derived EPCs that differentiate into mature BM-derived endothelial cells (ECs) and luminally incorporate into a subset of sprouting tumor neovessels. Notably, in later tumors, these BM-derived vessels are diluted with non-BM-derived vessels from the periphery, which accounts for purported differences in previously published reports. Furthermore, we show that specific ablation of BM-derived EPCs with α-particle-emitting anti-VE-cadherin antibody markedly impaired tumor growth associated with reduced vascularization. Our results demonstrate that BM-derived EPCs are critical components of the earliest phases of tumor neoangiogenesis.

30 March 2004 in Molecular Microbiology
Verified
Journal Article
Closed access
PDF file
CWCynthia B. Whitchurch
Cynthia B. Whitchurch
ALAndrew J. Leech
Andrew J. Leech
MYMichael D. Young
Michael D. Young
DKDerek Kennedy
Derek Kennedy
JSJennifer L. Sargent
Jennifer L. Sargent
JMJohn Mattick
John Mattick

1 November 2003 in Molecular Brain Research
Verified
Journal Article
Closed access
LTLotti Tajouri
Lotti Tajouri
AMAlbert Sleiman Mellick
Albert Sleiman Mellick
KAKevin Ashton
Kevin Ashton
ATAnthony E.G. Tannenberg
Anthony E.G. Tannenberg
RNRashed M. Nagra
Rashed M. Nagra
LGLyn Griffiths
Lyn Griffiths

1 January 2013 in Cancer Research
Verified
Journal Article
Open access
PDF file
PPPrue N. Plummer
Prue N. Plummer
RFRuth Freeman
Ruth Freeman
RTRyan J. Taft
Ryan J. Taft
JVJelena Vider
Jelena Vider
MSMichael Sax
Michael Sax
AMAlbert Sleiman Mellick
Albert Sleiman Mellick
Bone marrow–derived endothelial progenitor cells (EPC) contribute to the angiogenesis-dependent growth of tumors in mice and humans. EPCs regulate the angiogenic switch via paracrine secretion of proangiogenic growth factors and by direct luminal incorporation into sprouting nascent vessels. miRNAs have emerged as key regulators of several cellular processes including angiogenesis; however, whether miRNAs contribute to bone marrow–mediated angiogenesis has remained unknown. Here, we show that genetic ablation of miRNA-processing enzyme Dicer, specifically in the bone marrow, decreased the number of circulating EPCs, resulting in angiogenesis suppression and impaired tumor growth. Furthermore, genome-wide deep sequencing of small RNAs revealed tumor EPC-intrinsic miRNAs including miR-10b and miR-196b, which have been previously identified as key regulators of HOX signaling and adult stem cell differentiation. Notably, we found that both miR-10b and miR-196b are responsive to vascular endothelial growth factor stimulation and show elevated expression in human high-grade breast tumor vasculature. Strikingly, targeting miR-10b and miR-196b led to significant defects in angiogenesis-mediated tumor growth in mice. Targeting these miRNAs may constitute a novel strategy for inhibiting tumor angiogenesis. Cancer Res; 73(1); 341–52. ©2012 AACR.

1 June 2004 in Current Cancer Drug Targets
Verified
Journal Article
Closed access
PDF file
JNJiri Neuzil
Jiri Neuzil
Marco TomasettiMarco Tomasetti
Marco Tomasetti
AMAlbert Sleiman Mellick
Albert Sleiman Mellick
RARenata Alleva
Renata Alleva
BSBrian A. Salvatore
Brian A. Salvatore
MFMarc W. Fariss
Marc W. Fariss
In spite of unrelenting effort, the net incidence of neoplastic diseases appears not to have been curbed. While some types of cancer have been suppressed significantly, others are either stagnating or on the increase. Therefore, the need for a cure is imperative, in particularly a drug or combination of drugs that would be selective for malignant cells, i.e. with as low secondary toxicity as possible. Recent data strongly suggest that analogues of vitamin E, epitomised by the most studied α-tocopheryl succinate (α-TOS), may meet the need for the coveted drugs with a selective anti-neoplastic effect. The reasons for this optimism are reviewed in this article.